RecruitingPhase 1NCT06291987
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Studying Myeloproliferative neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Chicago
- Principal Investigator
- Anand PatelUniversity of Chicago Medicine Comprehensive Cancer Center
- Intervention
- Ivosidenib(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06291987 on ClinicalTrials.govOther trials for Myeloproliferative neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07441694Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation
- RECRUITINGPHASE2NCT07148947Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- RECRUITINGPHASE2NCT07228624Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesFred Hutchinson Cancer Center
- RECRUITINGNANCT07119970Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)University Hospital, Bordeaux
- RECRUITINGPHASE2NCT06661915A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)National Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentia
- RECRUITINGNCT07165535Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology NetworkUniversity of Milano Bicocca
- RECRUITINGNANCT05745285Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareUniversity of Miami